002393 力生制药
已收盘 09-02 15:00:00
资讯
新帖
简况
股市必读:力生制药(002393)8月31日董秘有最新回复
证券之星 · 09-01 02:57
股市必读:力生制药(002393)8月31日董秘有最新回复
力生制药:采立惠(www.cailihui.com)是力生制药子公司青春康源立和医药旗下品牌
证券之星 · 08-31 20:51
力生制药:采立惠(www.cailihui.com)是力生制药子公司青春康源立和医药旗下品牌
力生制药:自研1类及改良型新药项目主要围绕公司布局的治疗领域开展研发
证券之星 · 08-28
力生制药:自研1类及改良型新药项目主要围绕公司布局的治疗领域开展研发
股市必读:力生制药(002393)8月27日董秘有最新回复
证券之星 · 08-28
股市必读:力生制药(002393)8月27日董秘有最新回复
力生制药:公司70个品种纳入新版基药目录
证券之星 · 08-27
力生制药:公司70个品种纳入新版基药目录
力生制药:科改示范属于持续性改革任务
证券之星 · 08-27
力生制药:科改示范属于持续性改革任务
力生制药:下半年将从战略规划完善、产业并购、研发创新、市场拓展、生产运营优化、亏损主体治理等多方面落实改善举措
证券之星 · 08-24
力生制药:下半年将从战略规划完善、产业并购、研发创新、市场拓展、生产运营优化、亏损主体治理等多方面落实改善举措
力生制药(002393)2026年中报简析:净利润同比下降77.16%
证券之星 · 08-22
力生制药(002393)2026年中报简析:净利润同比下降77.16%
力生制药:成功研发并获批了替格瑞洛分散片
证券之星 · 08-21
力生制药:成功研发并获批了替格瑞洛分散片
力生制药:公司目前持有碘化钾片的药品批准文号
证券之星 · 08-21
力生制药:公司目前持有碘化钾片的药品批准文号
力生制药:公司高度重视细胞与基因治疗等前沿赛道
证券之星 · 08-21
力生制药:公司高度重视细胞与基因治疗等前沿赛道
力生制药(002393)披露对全资子公司提供委托贷款公告,8月20日股价上涨4.64%
证券之星 · 08-20
力生制药(002393)披露对全资子公司提供委托贷款公告,8月20日股价上涨4.64%
力生制药(002393)6月30日股东户数2.14万户,较上期减少17.84%
证券之星 · 08-20
力生制药(002393)6月30日股东户数2.14万户,较上期减少17.84%
力生制药:董事长外部活动未影响履职
证券之星 · 08-20
力生制药:董事长外部活动未影响履职
力生制药:公司不存在应披露而未披露的重大事项
证券之星 · 08-18
力生制药:公司不存在应披露而未披露的重大事项
力生制药:三鱼数智公司成立并布局AI算法软件开发
证券之星 · 08-17
力生制药:三鱼数智公司成立并布局AI算法软件开发
股市必读:力生制药(002393)8月14日董秘有最新回复
证券之星 · 08-17
股市必读:力生制药(002393)8月14日董秘有最新回复
力生制药:公司"十四五"期间市值实现了增长
证券之星 · 08-13
力生制药:公司"十四五"期间市值实现了增长
股市必读:力生制药(002393)8月12日董秘有最新回复
证券之星 · 08-13
股市必读:力生制药(002393)8月12日董秘有最新回复
力生制药:邀请长期持有股东以“战略顾问”或“智囊团”形式参与座谈
证券之星 · 08-12
力生制药:邀请长期持有股东以“战略顾问”或“智囊团”形式参与座谈
加载更多
公司概况
公司名称:
天津力生制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-04-23
主营业务:
天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山吲达帕胺片、三鱼氨酚咖匹林片、希福尼头孢地尼分散片、友好麻仁软胶囊、生化氢化可的松琥珀酸钠冻干粉针、碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。力生制药作为国家高新技术企业、国家企业技术中心、国家级绿色工厂,成功获评“医药医疗行业ESG绩效TOP20”,先后荣获中国上市公司董事会金圆桌奖、年度ESG价值传递奖、医药行业数字化转型标杆等多项荣誉。
发行价格:
45.00
{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":14.09,"timestamp":1788332628000,"preClose":14.32,"halted":0,"volume":2710679,"delay":0,"changeRate":-0.0161,"floatShares":300000000,"shares":308000000,"eps":0.4921,"marketStatus":"已收盘","change":-0.23,"latestTime":"09-02 15:00:00","open":14.26,"high":14.3,"low":14.06,"amount":38259400,"amplitude":0.0168,"askPrice":14.09,"askSize":25,"bidPrice":14.08,"bidSize":336,"shortable":0,"etf":0,"ttmEps":0.4921,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":5,"adr":0,"adjPreClose":14.32,"symbolType":"stock","openAndCloseTimeList":[[1788312600000,1788319800000],[1788325200000,1788332400000]],"highLimit":15.75,"lowLimit":12.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":308293069,"isCdr":false,"pbRate":0.98,"roa":"--","peRate":28.632392,"roe":"1.74%","epsLYR":1.62,"committee":0.557162,"marketValue":4344000000,"turnoverRate":0.009,"status":1,"floatMarketCap":4230000000},"requestUrl":"/m/hq/s/002393","defaultTab":"news","newsList":[{"id":"2664000045","title":"股市必读:力生制药(002393)8月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664000045?lang=zh_cn&edition=full","pubTime":"2026-09-01 02:57","pubTimestamp":1788202629,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘,力生制药报收于14.13元,下跌1.26%,换手率0.63%,成交量1.88万手,成交额2652.56万元。董秘最新回复投资者: 董秘,公司旗下“采立惠平台”曾获“数据要素×”省级奖项,并已取得两项计算机软件著作权。三鱼数智目前尚处于初创起步阶段,后续若出现业务层面重大节点突破,公司将按规定及时履行信息披露义务。当日关注点交易信息汇总:8月31日主力资金净流出201.77万元,占总成交额7.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100002580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005384","title":"力生制药:采立惠(www.cailihui.com)是力生制药子公司青春康源立和医药旗下品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663005384?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:51","pubTimestamp":1788180668,"startTime":"0","endTime":"0","summary":"三鱼数智目前尚处于初创起步阶段,后续若出现业务层面重大节点突破,公司将按规定及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100034352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","002393","BK1515","BK1161","BK0028","159938","BK0188","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662544120","title":"力生制药:自研1类及改良型新药项目主要围绕公司布局的治疗领域开展研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2662544120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662544120?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:03","pubTimestamp":1787900596,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月28日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好:公司首次透露“除鲲系列及2025年立项的改良型创新药项目外,还有部分自研1类及改良型新药处于不同的研发阶段”。请问:“自研1类新药”具体适应症方向是什么?谢谢力生制药回复:尊敬的投资者您好,公司自研 1 类及改良型新药项目主要围绕公司布局的治疗领域开展研发,相关项目正按既定研发计划有序推进,分处在不同研发节点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800030539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002393","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662315600","title":"股市必读:力生制药(002393)8月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662315600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662315600?lang=zh_cn&edition=full","pubTime":"2026-08-28 07:11","pubTimestamp":1787872278,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘,力生制药报收于14.24元,上涨0.35%,换手率0.66%,成交量1.99万手,成交额2823.05万元。投资者: 董秘好,公司及所属企业70个品种入选2026版基药目录,是此前24个品种近三倍数量,多地发文要求2个月内完成用药目录更新。氯化钾缓释片依托基药及集采接续采购的市场基础,市场拓展整体推进顺利。当日关注点交易信息汇总:主力资金净流入160.01万元,占总成交额5.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800013615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662737779","title":"力生制药:公司70个品种纳入新版基药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737779","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662737779?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:54","pubTimestamp":1787817249,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘好,公司及所属企业70个品种入选2026版基药目录,是此前24个品种近三倍数量,多地发文要求2个月内完成用药目录更新。首次纳入新品入院进展如何?力生制药回复:尊敬的投资者您好,公司 70 个品种纳入新版基药目录,目前正分批推进各省挂网及医院准入工作,各地平台、医疗机构落地节奏存在差异,新增品种入院工作按政策节点有序推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700034310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662779739","title":"力生制药:科改示范属于持续性改革任务","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662779739?lang=zh_cn&edition=full","pubTime":"2026-08-27 15:54","pubTimestamp":1787817248,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,公司入选“科改示范企业”,已近4年,请问:“科改示范”改革成效的“周期”到底是多长?另外,国企改革要求“刚性考核、刚性兑现,常态化不胜任退出”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700034308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661527914","title":"力生制药:下半年将从战略规划完善、产业并购、研发创新、市场拓展、生产运营优化、亏损主体治理等多方面落实改善举措","url":"https://stock-news.laohu8.com/highlight/detail?id=2661527914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661527914?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:51","pubTimestamp":1787575875,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月24日在投资者关系平台上答复投资者关心的问题。下半年公司将从战略规划完善、产业并购、研发创新、市场拓展、生产运营优化、亏损主体治理等多方面落实改善举措,积极推进重点产品申报上市、渠道拓展及内部降本提质,努力改善经营状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400034295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661218578","title":"力生制药(002393)2026年中报简析:净利润同比下降77.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661218578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661218578?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:12","pubTimestamp":1787350342,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期力生制药发布2026年中报。根据财报显示,力生制药净利润同比下降77.16%。截至本报告期末,公司营业总收入6.42亿元,同比下降12.29%,归母净利润7832.6万元,同比下降77.16%。按单季度数据看,第二季度营业总收入3.09亿元,同比下降14.47%,第二季度归母净利润2644.31万元,同比下降90.81%。财报体检工具显示:建议关注公司应收账款状况本文数据来源于力生制药2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200005093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250157","title":"力生制药:成功研发并获批了替格瑞洛分散片","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250157","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661250157?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:06","pubTimestamp":1787295985,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月21日在投资者关系平台上答复投资者关心的问题。谢谢力生制药回复:投资者您好,公司研究院依托天津市缓控释及固体分散体药物制剂重点实验室平台,着力开展高端制剂技术研究,成功研发并获批了替格瑞洛分散片。公司创新药管线整体在按既定研发节奏有序推进。除鲲系列及 2025 年立项的改良型创新药项目外,公司还有部分自研 1 类及改良型新药处于不同的研发阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100021983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002393","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661132250","title":"力生制药:公司目前持有碘化钾片的药品批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2661132250","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661132250?lang=zh_cn&edition=full","pubTime":"2026-08-21 15:06","pubTimestamp":1787295984,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月21日在投资者关系平台上答复投资者关心的问题。公司目前持有碘化钾片文号,曾有投资者建议公司引入普鲁士蓝、DPTA等WHO推荐品种。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100021982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002393","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661551832","title":"力生制药:公司高度重视细胞与基因治疗等前沿赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2661551832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661551832?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:12","pubTimestamp":1787274730,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月21日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好:公司在“十五五”战略中将细胞与基因治疗列为重点方向,已设立5亿元产业基金明确投向CGT领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100009608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002393","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660800262","title":"力生制药(002393)披露对全资子公司提供委托贷款公告,8月20日股价上涨4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660800262","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660800262?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:13","pubTimestamp":1787235192,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘,力生制药报收于15.1元,较前一交易日上涨4.64%,最新总市值为46.55亿元。该股当日开盘14.6元,最高15.58元,最低14.6元,成交额达1.45亿元,换手率为3.21%。近日,天津力生制药股份有限公司召开第八届董事会第七次会议,审议通过《关于对全资子公司天津生物化学制药有限公司提供委托贷款额度的议案》。公司将以自有资金为全资子公司生化制药提供4000万元额度的委托贷款,期限两年,年利率不超过2%,贷款额度在两年内滚动使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000045063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400019","title":"力生制药(002393)6月30日股东户数2.14万户,较上期减少17.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400019","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400019?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:36","pubTimestamp":1787218598,"startTime":"0","endTime":"0","summary":"证券之星消息,近日力生制药披露,截至2026年6月30日公司股东户数为2.14万户,较3月31日减少4650.0户,减幅为17.84%。在化学制药行业个股中,力生制药股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.7万户。从股价来看,2026年3月31日至2026年6月30日,力生制药区间跌幅为26.01%,在此期间股东户数减少4650.0户,减幅为17.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660704124","title":"力生制药:董事长外部活动未影响履职","url":"https://stock-news.laohu8.com/highlight/detail?id=2660704124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660704124?lang=zh_cn&edition=full","pubTime":"2026-08-20 11:33","pubTimestamp":1787196795,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月20日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000016842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002393","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467465","title":"力生制药:公司不存在应披露而未披露的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660467465?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:52","pubTimestamp":1787057528,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月18日在投资者关系平台上答复投资者关心的问题。公司严格按照监管规定履行信息披露义务,不存在应披露而未披露的重大事项。若有需披露的信息,公司将及时通过指定信息披露媒体对外公告,请广大投资者以公司公开公告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800039928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660801914","title":"力生制药:三鱼数智公司成立并布局AI算法软件开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2660801914","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660801914?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:51","pubTimestamp":1786971083,"startTime":"0","endTime":"0","summary":"证券之星消息,力生制药08月17日在投资者关系平台上答复投资者关心的问题。力生制药回复:尊敬的投资者您好,2026年4月,力生制药顺利通过世界无线局域网应用发展联盟的严格评估,成功获得“WAA WLAN创新应用项目”认证。2026年6月,力生制药持股70%的天津市三鱼数智健康科技公司成立。目前,三鱼数智公司经营范围中的AI算法软件开发主要指向健康咨询、大数据服务等数智化应用场景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700032681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","159036","BK0239","BK0028","002393"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660254170","title":"股市必读:力生制药(002393)8月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660254170","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660254170?lang=zh_cn&edition=full","pubTime":"2026-08-17 02:38","pubTimestamp":1786905493,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,力生制药报收于14.9元,下跌0.53%,换手率0.8%,成交量2.39万手,成交额3555.62万元。董秘最新回复投资者: 董秘好,北向资金与公募基金的“一进一出”,公司是否了解背后的原因?当日关注点交易信息汇总:8月14日主力资金净流出301.25万元,占总成交额8.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002393","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659522471","title":"力生制药:公司\"十四五\"期间市值实现了增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2659522471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659522471?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:51","pubTimestamp":1786625490,"startTime":"0","endTime":"0","summary":"力生制药回复:尊敬的投资者您好,关于董事长个人持股情况:张平先生2022年股权激励授予56,000股,2024年限制性股票激励计划新增授予限制性股票80,000股,期末持股136,000股,其持股变动主要来源于股权激励授予,体现了激励计划对其的约束与绑定。公司\"十四五\"期间市值实现了增长,2025年末市值较上年末提升23%;2025年度实现净利润4.16亿元,较2024年的1.85亿元大幅增长;全年分红金额达2.3亿元,推出\"中期+年度\"双分红周期,分红力度显著增强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300037472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659902878","title":"股市必读:力生制药(002393)8月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2659902878","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659902878?lang=zh_cn&edition=full","pubTime":"2026-08-13 02:25","pubTimestamp":1786559113,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,力生制药报收于14.85元,上涨0.41%,换手率0.73%,成交量2.2万手,成交额3264.92万元。公司诚挚欢迎您及更多长期关注力生制药的投资者亲临公司,与管理层面对面交流,围绕主业发展、品牌营销、市值管理等议题献计献策。当日关注点交易信息汇总:8月12日主力资金净流出65.45万元,占总成交额2.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300001589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658274559","title":"力生制药:邀请长期持有股东以“战略顾问”或“智囊团”形式参与座谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2658274559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658274559?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:12","pubTimestamp":1786522336,"startTime":"0","endTime":"0","summary":"您提出的邀请长期持有、深入了解公司的股东以“战略顾问”或“智囊团”形式参与座谈的构想,与公司持续深化投资者沟通、推动“消费者—投资者”双向转化的理念高度契合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200025984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002393","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788375247297,"stockEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0208},{"period":"3month","weight":-0.0181},{"period":"6month","weight":-0.2171},{"period":"1year","weight":-0.275},{"period":"ytd","weight":-0.1885}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0346},{"period":"3month","weight":-0.0287},{"period":"6month","weight":-0.0443},{"period":"1year","weight":0.0216},{"period":"ytd","weight":-0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21410人(较上一季度减少17.84%)","perCapita":"14022股","listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","registeredCapital":"30829万元","survey":" 天津力生制药股份有限公司的主营业务是医药产品研发、生产和销售。公司的主要产品是寿比山吲达帕胺片、三鱼氨酚咖匹林片、希福尼头孢地尼分散片、友好麻仁软胶囊、生化氢化可的松琥珀酸钠冻干粉针、碳酸氢钠片、盖胃平片、麻仁润肠丸、虎力散片。力生制药作为国家高新技术企业、国家企业技术中心、国家级绿色工厂,成功获评“医药医疗行业ESG绩效TOP20”,先后荣获中国上市公司董事会金圆桌奖、年度ESG价值传递奖、医药行业数字化转型标杆等多项荣誉。","listedPrice":45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}